WALTHAM, MA • 2020-08-04

BostonGene Announces Scientific Collaboration with Leading Cancer Center

5 min to read

Sophisticated Data Analytics to Predict Drug Response and Identify New Biomarkers in T-cell Lymphomas
Sophisticated Data Analytics to Predict Drug Response and Identify New Biomarkers in T-cell Lymphomas

WALTHAM, MA – August 4, 2020 - BostonGene Corporation (BostonGene), a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, today announced its collaboration with The Weinstock Laboratory, a translational research program focused on novel therapeutics for lymphoid malignancies, at Dana-Farber Cancer Institute, Inc.  The collaboration aims to define predictors of response to PI3 kinase inhibition in relapsed/refractory T-cell lymphomas.

The Weinstock Laboratory is leading the research efforts to reveal mechanisms of response and resistance, and possible cause of adverse effects to Duvelisib (PI3K delta & gamma inhibitor) in patients with T-cell lymphomas (TCLs).  Their work is supported by the Leukemia and Lymphoma Society and by Verastem, the makers of Duvelisib.  In this collaboration, BostonGene provides advanced computational analytics of genomic, transcriptomic, proteomic and multiplex imaging data sets to predict drug response and identify new biomarkers.  BostonGene’s software uses a set of unique deconvolution algorithms that reveal cellular content of a tumor and surrounding microenvironment using transcriptome next generation sequencing (NGS) data, and image analysis algorithms to elucidate spatial parameters of tumor microenvironment  distribution using immunofluorescence (IF) imaging data.

“We are excited to collaborate with BostonGene,” said David Weinstock, MD, at Dana- Farber Cancer Institute, Inc. “Improving patient outcomes is our top priority and by partnering with BostonGene we hope to accurately predict which patients will benefit from treatment by identifying new biomarkers that could be useful for other patients with cancer.  The results have the potential to bring significant advantages to physicians as they make individual treatment decisions.”

“BostonGene is thrilled to collaborate with the Weinstock Laboratory at Dana- Farber Cancer Institute, Inc.” said Andrew Feinberg, President and CEO of BostonGene. “Our sophisticated analysis of RNAseq and exome sequencing will identify genomic and transcriptional alterations that could serve as predictive biomarkers of response and resistance to PI3 kinase inhibition that could ultimately improve patient outcomes. “

About BostonGene Corporation

BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit www.BostonGene.com.

Erin O’Reilly

Senior Director

+1-617-283-2285

Erin.Oreilly@BostonGene.com